Does the media prefer EVMN or RIGL?

In the previous week, Evommune and Evommune both had 2 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Evommune's score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, EVMN or ALMS?

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $10M 21.29 -$68.87M -$11.03 N/A Alumis $24.05M 35.30 -$243.32M -$3.86 N/A

Is EVMN or ALMS more profitable?

Evommune has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Evommune's return on equity of -62.63% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Alumis -5,933.46% -93.15% -74.50%

Does the media favor EVMN or ALMS?

In the previous week, Alumis had 9 more articles in the media than Evommune. MarketBeat recorded 11 mentions for Alumis and 2 mentions for Evommune. Alumis' average media sentiment score of 0.55 beat Evommune's score of 0.00 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JBIO or EVMN more profitable?

Jade Biosciences' return on equity of -49.11% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Evommune N/A -62.63% -40.55%

Does the media prefer JBIO or EVMN?

In the previous week, Jade Biosciences and Jade Biosciences both had 2 articles in the media. Jade Biosciences' average media sentiment score of 0.91 beat Evommune's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRVS or EVMN more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Evommune N/A -62.63% -40.55%

Does the media refer more to CRVS or EVMN?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.79 beat Evommune's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ODTX or EVMN more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Odyssey Therapeutics N/A N/A N/A Evommune N/A -62.63% -40.55%

Does the media favor ODTX or EVMN?

In the previous week, Odyssey Therapeutics had 5 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Odyssey Therapeutics and 2 mentions for Evommune. Odyssey Therapeutics' average media sentiment score of 0.35 beat Evommune's score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evommune (EVMN) Competitors

$5.86 -0.19 (-3.06%)

Closing price 03:59 PM Eastern

Extended Trading

$5.89 +0.03 (+0.49%)

As of 08:00 PM Eastern

Compare

EVMN vs. RIGL, ALMS, JBIO, CRVS, and ODTX

Should you buy Evommune stock or one of its competitors? Evommune's main competitors and comparable companies include Rigel Pharmaceuticals (RIGL), Alumis (ALMS), Jade Biosciences (JBIO), Corvus Pharmaceuticals (CRVS), and Odyssey Therapeutics (ODTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evommune compare to Rigel Pharmaceuticals?

Evommune (NYSE:EVMN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Evommune currently has a consensus target price of $30.80, indicating a potential upside of 425.15%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 25.16%. Given Evommune's stronger consensus rating and higher possible upside, research analysts clearly believe Evommune is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Evommune. Evommune is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

Rigel Pharmaceuticals has a net margin of 116.30% compared to Evommune's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 31.1% of Evommune shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Evommune and Evommune both had 2 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Evommune's score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats Evommune on 9 of the 15 factors compared between the two stocks.

How does Evommune compare to Alumis?

Evommune (NYSE:EVMN) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Evommune has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Evommune's return on equity of -62.63% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Alumis	-5,933.46%	-93.15%	-74.50%

In the previous week, Alumis had 9 more articles in the media than Evommune. MarketBeat recorded 11 mentions for Alumis and 2 mentions for Evommune. Alumis' average media sentiment score of 0.55 beat Evommune's score of 0.00 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A
Alumis	$24.05M	35.30	-$243.32M	-$3.86	N/A

Evommune presently has a consensus price target of $30.80, indicating a potential upside of 425.15%. Alumis has a consensus price target of $33.27, indicating a potential upside of 407.21%. Given Evommune's higher possible upside, equities analysts clearly believe Evommune is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Alumis beats Evommune on 7 of the 12 factors compared between the two stocks.

How does Evommune compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Evommune has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A

In the previous week, Jade Biosciences and Jade Biosciences both had 2 articles in the media. Jade Biosciences' average media sentiment score of 0.91 beat Evommune's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences presently has a consensus target price of $51.75, indicating a potential upside of 285.62%. Evommune has a consensus target price of $30.80, indicating a potential upside of 425.15%. Given Evommune's higher possible upside, analysts plainly believe Evommune is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69

Jade Biosciences' return on equity of -49.11% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Evommune	N/A	-62.63%	-40.55%

Summary

Jade Biosciences and Evommune tied by winning 5 of the 10 factors compared between the two stocks.

How does Evommune compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Evommune. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A

Corvus Pharmaceuticals' return on equity of -36.15% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Evommune	N/A	-62.63%	-40.55%

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.79 beat Evommune's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 254.23%. Evommune has a consensus price target of $30.80, indicating a potential upside of 425.15%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 31.1% of Evommune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Corvus Pharmaceuticals beats Evommune on 7 of the 11 factors compared between the two stocks.

How does Evommune compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Odyssey Therapeutics had 5 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Odyssey Therapeutics and 2 mentions for Evommune. Odyssey Therapeutics' average media sentiment score of 0.35 beat Evommune's score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Odyssey Therapeutics has higher earnings, but lower revenue than Evommune. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A

Odyssey Therapeutics currently has a consensus price target of $35.33, indicating a potential upside of 104.95%. Evommune has a consensus price target of $30.80, indicating a potential upside of 425.15%. Given Evommune's higher possible upside, analysts plainly believe Evommune is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69

Odyssey Therapeutics' return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

Summary

Odyssey Therapeutics beats Evommune on 6 of the 10 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$219.57M	$3.93B	$7.27B	$23.13B
Dividend Yield	N/A	3.65%	2.52%	3.72%
P/E Ratio	-0.53	9.71	193.11	21.01
Price / Sales	21.29	1,149.10	561.77	22.63
Price / Cash	N/A	118.50	77.16	37.05
Price / Book	0.90	16.95	10.71	4.73
Net Income	-$68.87M	-$22.69M	$3.50B	$1.07B
7 Day Performance	-10.80%	-4.83%	-3.18%	-0.48%
1 Month Performance	-44.51%	-12.20%	-6.61%	-3.50%
1 Year Performance	N/A	8.87%	3.69%	7.66%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.3254 of 5 stars	$5.87 -3.1%	$30.80 +425.1%	N/A	$219.57M	$10M	N/A	48	News Coverage Analyst Forecast
RIGL Rigel Pharmaceuticals	4.5042 of 5 stars	$48.72 +1.5%	$59.00 +21.1%	+73.2%	$887.91M	$294.28M	2.99	174
ALMS Alumis	3.7508 of 5 stars	$6.97 +3.0%	$33.27 +377.4%	+59.0%	$876.28M	$24.05M	N/A	239	News Coverage Options Volume
JBIO Jade Biosciences	2.1885 of 5 stars	$14.15 +2.8%	$51.75 +265.7%	+54.2%	$875.74M	N/A	N/A	55
CRVS Corvus Pharmaceuticals	2.1544 of 5 stars	$10.21 -1.9%	$33.33 +226.5%	+45.0%	$875.70M	N/A	N/A	37	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. RIGL, ALMS, JBIO, CRVS, and ODTX

How does Evommune compare to Rigel Pharmaceuticals?

Summary

How does Evommune compare to Alumis?

Summary

How does Evommune compare to Jade Biosciences?

Summary

How does Evommune compare to Corvus Pharmaceuticals?

Summary

How does Evommune compare to Odyssey Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. RIGL, ALMS, JBIO, CRVS, and ODTX

How does Evommune compare to Rigel Pharmaceuticals?

Do analysts rate EVMN or RIGL?

Which has preferable earnings & valuation, EVMN or RIGL?

Is EVMN or RIGL more profitable?

Do insiders and institutionals believe in EVMN or RIGL?

Does the media prefer EVMN or RIGL?

Summary

How does Evommune compare to Alumis?

Is EVMN or ALMS more profitable?

Does the media favor EVMN or ALMS?

Which has better valuation & earnings, EVMN or ALMS?

Do analysts prefer EVMN or ALMS?

Summary

How does Evommune compare to Jade Biosciences?

Which has higher valuation and earnings, JBIO or EVMN?

Does the media prefer JBIO or EVMN?

Do analysts recommend JBIO or EVMN?

Is JBIO or EVMN more profitable?

Summary

How does Evommune compare to Corvus Pharmaceuticals?

Which has preferable valuation and earnings, CRVS or EVMN?

Is CRVS or EVMN more profitable?

Does the media refer more to CRVS or EVMN?

Do analysts rate CRVS or EVMN?

Do insiders and institutionals believe in CRVS or EVMN?

Summary

How does Evommune compare to Odyssey Therapeutics?

Does the media favor ODTX or EVMN?

Which has stronger valuation and earnings, ODTX or EVMN?

Do analysts prefer ODTX or EVMN?

Is ODTX or EVMN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools